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Pattern recognition receptors (PRRs) expressed on immune cells are crucial for the early
detection of invading pathogens, in initiating early innate immune response and in orches-
trating the adaptive immune response. PRRs are activated by specific pathogen-associated
molecular patterns that are present in pathogenic microbes or nucleic acids of viruses or
bacteria. However, inappropriate activation of these PRRs, such as the Toll-like receptors
(TLRs), due to genetic lesions or chronic inflammation has been demonstrated to be a
major cause of many hematological malignancies. Gain-of-function mutations in the TLR
adaptor protein MYD88 found in 39% of the activated B cell type of diffuse large B cell
lymphomas and almost 100% of Waldenström’s macroglobulinemia further highlight the
involvement of TLRs in these malignancies. MYD88 mutations result in the chronic activa-
tion of TLR signaling pathways, thus the constitutive activation of the transcription factor
NFκB to promote cell survival and proliferation. These recent insights into TLR pathway
driven malignancies warrant the need for a better understanding of TLRs in cancers and
the development of novel anti-cancer therapies targetingTLRs.This review focuses onTLR
function and signaling in normal or inflammatory conditions, and how mutations can hijack
the TLR signaling pathways to give rise to cancer. Finally, we discuss how potential ther-
apeutic agents could be used to restore normal responses to TLRs and have long lasting
anti-tumor effects.
Keywords: cancer, drug targets, inflammation, lymphoma, MYD88 L265P, pattern recognition receptors, self-nucleic
acid,Toll-like receptors
INTRODUCTION
Pattern recognition receptors (PRRs) are germline-encoded recep-
tors with the ability to relay “danger signals” to the host in
order to mediate an early innate immune response. The term
“pattern recognition receptors” comes from their ability to recog-
nize specific pathogen-associated molecular patterns (PAMPs) and
danger-associated molecular patterns (DAMPs) (1, 2). PRRs can
be broadly divided into five distinct subfamilies: Toll-like recep-
tors (TLRs), C-type lectin receptors (CLRs), NOD-like receptors
(NLRs), RIG-1-like receptors (RLRs), and AIM2-like receptors
(ALRs). These PRR subfamilies differ in their structures, localiza-
tion patterns, the distinct types of ligands they recognize, and the
activation of specific intracellular signaling cascades to mediate a
range of responses such as the regulation of gene transcription,
cell activation, and proliferation, and the production of pro-
inflammatory cytokines, chemokines,and anti-viral molecules (3).
One of the most well characterized PRR is the TLR (4). TLRs are
type I transmembrane proteins with an extracellular domain con-
sisting of leucine-rich repeats and a cytoplasmic domain homol-
ogous to that of the interleukin (IL)-1 receptor (5, 6). These
evolutionarily conserved receptors are absolutely critical for the
host innate immune response against many pathogens (7). Acti-
vation of TLRs depends on the number of different ligands they
may encounter, which is by large, governed by their subcellular
localization. Much insight has been gained in recent years on the
localization and trafficking of TLRs and the important roles their
localization play in the way they recognize their ligands. TLRs can
be divided into two groups based on their subcellular localization,
either on the cell surface or within intracellular compartments
(8). Given the ability of TLRs to recognize a large number of
pathogen-associated ligands such as glycoproteins, lipopolysac-
charides, flagellin, and viral double-strand or single-strand RNAs
or DNAs, TLRs have emerged as an important family of PRRs
in shaping both the innate and adaptive immunity (7). How-
ever, inappropriate activation of these pathways can often lead
to chronic inflammatory diseases or cancer.
This review will focus on TLRs and malignancies associated
with the dysregulation of TLR signaling pathways. TLR activa-
tion by somatic MYD88 mutations and chronic inflammations has
been implicated in a number of hematological malignancies. Tar-
geting the TLR signaling network has gained increasing attention
from researchers and clinicians seeking strategies to achieve long
lasting anti-tumor outcomes. Here, we discuss the signal trans-
duction and immune regulation by TLRs and the immunological
malignancies that manifest from dysregulation of TLR pathways,
including how targeting these pathways could be an attractive
therapeutic regime.
TOLL-LIKE RECEPTORS
Toll-like receptors are probably the best studied PRRs that
participate in the first line of host defense against pathogens. TLRs
belong to an evolutionarily conserved family of adaptors sharing
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homology with the Drosophila protein Toll, which is best known
for its essential role in establishing dorsoventral polarity during
embryogenesis in insects (9). Amino acid sequencing and hydropa-
thy profiling identified Toll as a type I transmembrane protein with
a membrane-spanning segment and multiple tandem leucine-rich
repeats directed at the extracellular surface (9). Further biochem-
ical and functional studies conducted on the receptor Toll and its
leucine repeats established it as a critical pathogen sensing receptor
for recognizing bacteria and fungus in Drosophila (10). This study
later became critical for the discovery of Toll-like homologs (TLRs)
in mammals as mediators of the innate immunity (4, 10, 11).
A total of 10 TLRs have been identified in humans and 12 in
mice (7). Due to the small repertoire of TLRs available to rec-
ognize a virtually unlimited combination of pathogen-associated
patterns, each individual TLR must be able to detect and respond
to a large number of pathogens ranging from bacteria, fungi,
protozoa, and viruses (12, 13). For instance, TLRs 1, 2, and 6
recognize lipo-, glycol-, and acyl-peptides expressed on the sur-
faces of many Gram-positive and Gram-negative bacteria and
mycobacteria (7). Additional cooperation between TLRs 1, 2, and
6 enables them to further discriminate different microbial com-
ponents (14). TLR4 recognizes lipopolysaccharide components of
the cell wall of Gram-negative bacteria through its co-receptor
MD-2 (15, 16). In addition, TLR4 can also recognize endoge-
nous ligands such as heat-shock proteins, extracellular matrix
components including fibronectin, hyaluronic acid, and heparin
sulfate in response to tissue injury (7). The nucleic acid sens-
ing subfamily of TLRs consists of TLRs 3, 7, and 9 and exhibit
unique endosomal localization in contrast to the surface expres-
sion of the other TLRs (17). These TLRs have the ability to detect
nuclear material such as ssRNAs, dsRNAs, and dsDNAs and are
vital for anti-viral responses (18–21). Importantly, these nucleic
acid sensing TLRs must discriminate between foreign and self-
nuclear material to prevent autoimmunity. Due to the relative lack
of specificity of TLRs compared to the B cell receptors (BCRs),
restriction of self-TLR activation must be achieved through other
means. TLRs are protected from engaging self-nuclear material
by Unc93b mediated restriction to the endosome (22). In such
way, self-nucleic acids are prevented from entering the endosome,
but foreign material can enter via endocytosis and be processed
in the acidified endosomes in order to activate the endosomal
TLRs (23, 24).
Together, the 10 human TLRs can recognize a virtually unlim-
ited combination of pathogens, however, the downstream signal-
ing pathways they share are striking. All TLRs except for TLR3
signal through the adaptor protein MYD88 (25). Upon ligand
binding, TLRs induce the dimerization of their ectodomains,
bringing the cytoplasmic TIR domains together, and initiat-
ing a signaling cascade via signal adaptor molecules. The four
main TLR adaptor molecules are the myeloid differentiation
response protein 88 (MYD88), Toll-interleukin 1 receptor (TIR)
domain containing adaptor protein (TIRAP; also known as MAL),
TIRAP inducing IFN-β (TRIF), and TRIF-related adaptor mol-
ecule (TRAM) (Figure 1). These adaptors are used in various
combinations by the different TLRs, but these signaling pathways
can be broadly classified into either MYD88 dependent or MYD88
independent.
MYD88 DEPENDENT TLR SIGNALING
With the exception of TLR3, all TLRs initiate a MYD88-dependent
signaling pathway (26). The signal adaptor protein MYD88 con-
tains two main conserved protein domains; a C-terminal TIR
and a N-terminal death domain (DD) (27, 28). Upon TLR acti-
vation, MYD88 is recruited to the TIR domain of the activated
TLR via TIR–TIR interaction (29). The serine–threonine kinase,
IL1-receptor associated kinase 4 (IRAK4), is then recruited to
MYD88 through the interaction of their DD domains. IRAK4
then recruits and phosphorylates IRAK1 and IRAK2 to form a
structure known as the “Myddosome” (30). Phosphorylation of
IRAKs 1 and 2 allows them to interact with the E3 ubiquitin ligase,
TRAF6, via their TRAF binding domain (31). TRAF6 then ubiq-
uitylates and activates TAK1 (32), which has the dual ability to
activate both the NFκB pathway and the mitogen-activated pro-
tein kinase (MAPK) pathway (26). In resting cells, NFκB dimers
are sequestered in an inactive form in the cytoplasm by the IκB
protein (33). During NFκB activation, TAK1 phosphorylates and
activates IκB kinase β (IKKβ), which in turn phosphorylates IκB,
targeting it for proteosomal degradation (34). The degradation
of IκB releases NFκB, enabling it to enter the nucleus and bind to
sequences known as κB sites to activate transcription of genes (35).
TAK1 also activates the MAPK pathway, leading to the activation
of c-Jun N-terminal kinase (JNK), which activates the Jun family
of transcription factors (36) (Figure 1).
The MYD88-dependent pathway can be initiated by TLR5 and
TLR7-9 using the adaptor MYD88 alone, while the adaptor protein
TIRAP is required with MYD88 to initiate signaling downstream
of TLR2 and TLR4 (37, 38). In this subset of TLRs, TIRAP acts
as a sorting molecule that is necessary for efficient recruitment
of MYD88 to the activated TLRs to initiate signal transduction
to activate NFκB and produce pro-inflammatory cytokines (39).
During TLR 7 and 9 activation, MYD88 also recruits TRAF3 to
activate TBK1 and IKKε, which phosphorylates the transcription
factor interferon-regulatory factor 7 (IRF7) and leads to IFN-α
production (40, 41). IFN-α production, as with production of
other IFNs, is particularly important for anti-viral responses (42)
(Figure 1).
MYD88 INDEPENDENT TLR SIGNALING
MYD88-independent TLR3 signaling requires the adaptor mole-
cule TRIF to activate downstream signaling pathways, including
the activation of IRF3 and the production of IFN-β (43). TRIF
has also been known to participate in signaling downstream of
TLR4 for type 1 interferon responses (44). Upon ligand binding,
TRIF recruits TRAF3, which acts as a scaffold for the activation
of the IKKs, TBK1, and IKKε, leading to the phosphorylation and
activation of the transcription factor IRF3 and IFN-β transcrip-
tion (45, 46). While TLR3 can activate this pathway using TRIF
alone, the adaptor TRAM is required for TLR4, where TRAM
facilitates the recruitment of TRIF to TLR4 (47). Upon the acti-
vation of TRIF, TRAF6 is recruited, which then activates TAK1
through ubiquitination and leading to the subsequent activation
of NFκB (48)(Figure 1). Interestingly, TRAF3 has been shown to
play important roles in regulating both the MYD88 dependent
and independent response through its differential ubiquitination
(49). MYD88-independent signaling triggers the non-degradative
Frontiers in Immunology | Tumor Immunity July 2014 | Volume 5 | Article 367 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wang et al. TLR and cancer: MYD88 mutation and inflammation
FIGURE 1 | Signal transduction downstream of MYD88-dependent
and independent pathways. Activation of Toll-like receptors (TLRs)
through binding of their ligand leads to receptor dimerization and the
recruitment of adaptor proteins such as MYD88, TIRAP, TRIF, and
TRAM. Most of the TLRs form homodimers upon activation while TLR2
can also form heterodimers with either TLR6 or TLR1 to recognize
diacylated and triacylated lipopeptides, respectively. Downstream
signals are propagated through the activation of IRAKs-TRAF6 and the
IKK complex, culminating in the activation of transcription factors such
as nuclear factor-κB (NFκB) and interferon-regulatory factors (IRFs),
which regulate the production of pro-inflammatory cytokines and type
1 interferon (IFNs).
self-ubiquitination of TRAF3, promoting IRF3 activation. On
the other hand, the MYD88-dependent pathway results in the
degradative ubiquitination of TRAF3 and the activation of TAK1
(49). In this manner, TRAF3 acts to balance pro-inflammatory
and IFN response by the MYD88 dependent and independent
pathways.
HEMATOLOGICAL MALIGNANCY AND MYD88 MUTATION
Inappropriate activation of TLRs due to the somatic acquisition of
gain-of-function mutations in the TLR adaptor protein MYD88
has been implicated in many hematological malignancies. Acti-
vated B cell type diffuse large B cell lymphoma (ABC-DLBCL),
a particularly aggressive subtype of DLBCL whose pathogene-
sis relies on constitutively active NFκB, frequently accumulates
MYD88 mutations. 39% of tumor samples contain mutations in
MYD88, and strikingly, 29% of those mutations result in a sin-
gle nucleotide change from leucine into proline at position 265
(L265P) (50). shRNA knockdown of MYD88 in lymphoma cell
lines demonstrated that MYD88 mutations are critical for their
survival and high NFκB transcription factor activity (50). A hyper-
phosphorylated isoform of IRAK1 was strongly associated with the
L265P mutant form of MYD88, suggesting that this mutation is a
gain-of-function mutation that leads to the constitutive activation
of downstream IRAKs (50). The effects of the L265P mutation
include increased NFκB activity as well as increased JAK-STAT3
signaling and the production of pro-inflammatory cytokines such
as IL6, IL10, and IFN-β (50). The production of these cytokines
further activates JAK-STAT3 signaling as part of an autocrine
loop that enhances the survival of the lymphoma cells (51, 52)
(Figure 2).
MYD88 mutations have since emerged in a number of other
human malignancies, with the L265P mutation found in includ-
ing almost 100% of Waldenström’s macroglobulinemia (WM),
2–10% of chronic lymphocytic leukemia (CLL), 69% of cutaneous
diffuse large B cell lymphoma (CBCL), and 38% of primary central
nervous system lymphoma (PCNSL) (previously reviewed in Ref.
(53)). However, the effect of single MYD88 L265P mutation on
tumor growth is confounded by the accumulation of other poten-
tial damaging mutations in the same malignant clones. Recently,
a retroviral gene transfer strategy to study the effects of single
MYD88 mutation in other wise normal mature B cells found
that the MYD88 L265P mutation alone was able to drive limited
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FIGURE 2 | Inflammation induces B cell activation. TLR activation by
nucleic acid–protein complexes derived from inflammation and MYD88
mutation B cell antigen receptor (BCR) delivers nucleic acids–protein
complexes to TLR-containing endosomes, where MYD88 initiates the
activation of intracellular signaling pathways, such as NFκB. Intriguingly,
oncogenic MYD88 mutations require intact TLR apparatuses to recognize
nucleic acids. One of the potential sources for TLR ligands is nucleic
acid–protein complexes derived from inflammation and chronic infection. A
subset of ABC-DLBCL shows constitutively activation of JAK-STAT3
pathway, presumably due to autocrine stimulation by IL-6 and IL-10. The
activation of cytokine receptor signaling can also be induced by
inflammatory cytokines in the milieu of inflammation and chronic infection.
rounds of mitogen independent B cell proliferation both in vitro
and in vivo (54). Nevertheless, the drive for B cell proliferation
was dependent on intact nucleic acid sensing TLR activity since
Unc93b13d mutation or Tlr9 deficiency inhibited the prolifera-
tion of MYD88 L265P B cells in vitro (54). Other studies have
also shown that oncogenic MYD88 depends on TLRs by using the
depletion of UNC91B1, PRAT4A, and CD14 in ABC-DLBCL lines
as well as by using pharmacological inhibitors to TLR7 and TLR9
(55). Given that intact TLR activity is critical for lymphoma cells
carrying MYD88 mutations, targeting this pathway appears to be
attractive for treating these malignancies. Indeed, blocking endo-
some acidification using chloroquine selectively inhibits MYD88
L265P mutation driven B cell proliferation in vitro (54). The use of
chloroquine to treat hematological malignancies should be further
explored, as evidence suggests that there is a strong involvement of
the activation of nucleic acid sensing TLRs that depends on normal
endosome acidification in promoting proliferative abnormality in
these tumors.
HEMATOLOGICAL MALIGNANCY AND INFLAMMATION
Remarkably, inflammation enables most of the key cellular and
molecular capabilities that are required for carcinogenesis, such
as genomic instability, proliferative abnormality, and reprogram-
ing of the stromal environment (56). Although, the mechanisms
by which inflammation promotes neoplastic transformation are
not fully understood, it is apparent that, in many cases, tumor
development is linked to chronic inflammation (57, 58).
The link between inflammation and tumor formation was first
speculated by Virchow in the 1800s as he observed that tissue
injury and inflammation induced by irritants could promote cell
proliferation (59). Infection has been accepted as a major driver of
inflammation-induced tumorigenesis, with up to one-fifth of all
cases of cancer associated with infection (60, 61). For instance, per-
sistent Helicobacter pylori infection is associated with gastric can-
cer and mucosa-associated lymphoid tissue (MALT) lymphoma,
infections with hepatitis B and C viruses are associated with hepa-
tocellular carcinoma, and infections with Bacteroides species are
linked to colon cancer (62, 63). The inflammatory response trig-
gered by infection is a part of normal host defense to eliminate
the pathogen. However, some tumorigenic pathogens subvert host
immunity and establish persisting infections, leading to chronic
inflammation (64, 65).
Persistent inflammation establishes a microenvironment,
which contains macrophages, dendritic cells, natural killer cells,
and T and B lymphocytes in addition to the surrounding stroma
(66) (Figure 3A). These diverse cells communicate with each
other by means of direct contact or cytokine and chemokines,
which influence tumor formation and growth (67, 68). This net-
work of inflammatory cells promotes the formation of cancerous
cells, which further complicates the initial chronic inflamma-
tion induced by infection. The neoplastic cells trigger anti-tumor
immunity, which further adds to the established inflammation.
Early during tumor formation, whether tumor-promoting inflam-
mation or anti-tumor immunity follows seems to be stochastic and
is influenced by a combination of cell-intrinsic and cell-extrinsic
processes (69,70). In established cancers,pro-tumor inflammation
seems to be favored, as without therapeutic intervention advanced
tumors rarely regress.
Continuous stimulation of TLRs by microbial products consti-
tutively engages the activation of the NFκB and STAT3 transcrip-
tion factors, which exert pro-cancerous activity through multiple
effectors (62, 71, 72). Additionally, the production of cytokines
by the host inflammatory cells activates these transcription fac-
tors (62) (Figure 2). These cytokines facilitate the establishment
of feed-forward signal amplification loops, which ultimately pro-
mote cell proliferation and resistance to cell death. For instance,
the expression of the anti-apoptotic proteins Bcl-2 and Bcl-XL
is promoted by both NFκB and STAT3, as is the expression
of c-IAP1, c-IAP2, Mcl-1, c-FLIP, and survivin (62, 72). More-
over, both transcription factors interfere with p53 expression
and function, representing another potential tumor-promoting
mechanism (73).
An additional mechanism linking inflammation to tumor for-
mation is the expression of activation-induced cytidine deaminase
(AID), an enzyme that promotes immunoglobulin gene class
switching by catalyzing deamination of cytosines in DNA (74).
In addition to B lymphocytes, where it was originally discov-
ered, AID is overexpressed in many cancers of diverse origin,
and its expression is induced by inflammatory cytokines in a
NFκB-dependent manner (74). AID induces genomic instability
and increases mutation probability during the error-prone joining
of double-stranded DNA breaks. This mutagenic process causes
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FIGURE 3 | Role of Helicobacter pylori in the pathogenesis of
gastric MALT lymphoma. (A) H. pylori infection results in buffering of
the gastric pH, which allows immune cell infiltration and the
establishment of MALT. The presentation of H. pylori antigens by
dendritic cells recruits and activates T cell responses, which enhance B
cell activation through CD40–CD40L interactions. (B) MALT lymphoma
may result from the transformation of a single B cell clone, which
initially formed part of the polyclonal B lymphocyte response against H.
Pylori. Both direct activation of TLR signaling by H. pylori and chronic
BCR signaling from engagement of autoantigens from damaged
stomach cells and the B cell receptor, in addition to T cell-B cell
co-stimulation could be involved in the expansion of the single
neoplastic B cell clone. Acquisition of additional genomic lesions could
transform MALT lymphomas into more aggressive DLBCL.
mutations in critical cancer-associated genes such as Tp53 and
c-Myc (75, 76).
HELICOBACTER PYLORI, INFLAMMATION AND MALT
LYMPHOMA
MALT lymphomas, which occur in the context of chronic inflam-
mation caused by infectious agents, such as H. pylori (gastric
lymphoma), Chlamydia psittacii (ocular adnexal lymphoma), and
Borrelia burgdorferi (cutaneous lymphoma) are a prime example
of lymphoid malignancies associated with chronic inflammation
(77, 78). Interestingly, in some patients, gastric MALT lymphoma
and diffuse large B cell lymphoma (DLBCL) co-occur, indicating
that MALT lymphomas can develop into more aggressive DLBCL
(79). The pathogenesis of MALT lymphoma involves several steps,
which result in the transformation of a single B cell clone, ini-
tially part of the polyclonal B lymphocyte response against H.
Pylori into a monoclonal tumor (78) (Figure 3B). Under physio-
logical conditions, the stomach lacks MALT because the low pH
prevents the survival of lymphocytes in the gastric wall. However,
H. pylori infection results in buffering of the gastric pH owing to
the secretion of bacterial urease. The decreased acidity of stomach
environment, along with the presence of the infection, triggers
lymphoid infiltration and the establishment of MALT (78).
Subsequently, the continuous presence of H. pylori induces an
upregulation of TLR4 and MD-2 expression in gastric epithelial
cells, which contributes to establishing a persistent inflammatory
environment (80–82). Although, the role of TLRs in the pathogen-
esis of MALT lymphoma has been poorly investigated, the immune
response to chronic stimulation by H. pylori infection is thought
to induce NFκB activation in B cells, which plays a crucial part in
the development of MALT lymphoma (83, 84). In addition, the
presentation of H. pylori by dendritic cells recruits and activates
T cell responses, which enhance B cell activation through CD40–
CD40L interactions (85) (Figure 3A). Thus, both direct activation
of TLR signaling by H. pylori and T cell-mediated B cell activation
could be involved in the pathogenesis of MALT lymphoma (86).
Interestingly, several lines of evidence indicate that chronic
antigen stimulation precedes MALT lymphoma pathogenesis. The
rearranged IGVH genes from MALT lymphomas have a high fre-
quency of variants, which have been implicated in autoantibody
production (87). In addition, approximately half of the MALT
lymphoma cases display evidence of intraclonal variation in the
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IGVH locus, indicating that continued antigenic stimulation is a
key driver of clonal B cell expansion (87). As both somatic hyper-
mutation and intraclonal variations are antigen-driven processes,
their occurrence in gastric MALT lymphoma strongly indicates a
role for antigens during both initiation and progression of this
neoplasm.
Remarkably, tumor-derived immunoglobulins from MALT
lymphomas bind to various autoantigens as well as H. pylori
with varying affinities (87). The autoantigens include DNA and
stomach-associated antigens, which could be abundant in the
MALT-microenvironment under a situation of continuous inflam-
mation. Given that H. pylori eradication with antibiotics is the
preferred therapy for patients with H. pylori-positive gastric MALT
lymphoma (88, 89), and the evidence that MALT lymphoma cells
proliferate when stimulated with H. pylori in tissue culture, one
possible hypothesis is that neoplastic B cells receive proliferative
signals from both the B cell receptor and TLRs, which are contin-
uously and simultaneously engaged by self-antigens and LPS from
H. pylori respectively. Thus, the eradication of H. pylori by antibi-
otics disrupts a critical ‘weak’ link in the inflammatory process,
which gradually resolves and shuts off the supply of autoantigens
available to lymphoma cells.
ROLE OF INFLAMMATION AND CYTOKINES IN CLL AND
MULTIPLE MYELOMA
It is apparent that antigenic stimulation, autoimmunity, and
inflammation contribute to the development of CLL (90). One
mechanism through which these stimuli promote CLL develop-
ment is induction of B cell activating factor (BAFF), a member
of the TNF family, recently shown to accelerate development of
CLL-like disease in mice (91). In addition, cytokines such as IL6
and interactions with bone marrow stromal cells support CLL
expansion and suppress apoptosis through the expression of Bcl-
2, Survivin, and Mcl-1 (92, 93). Increased IL6 production activates
the JAK-STAT, MAPK, and PI3K pathways to promote cell survival,
proliferation, and resistance to apoptosis (94–96), with the con-
stitutive activation of STAT3 being a hallmark for CLLs (97, 98).
Similarly, through the secretion of IL6, TNF-α, and BAFF, bone
marrow stromal cells promote the survival of neoplastic plasma
cells and also confer drug resistance in multiple myeloma (99).
Interestingly, IL6-deficient mice are resistant to induction of mul-
tiple myeloma (100, 101). Thus, despite cell-intrinsic constitutive
NFκB activation, multiple myeloma cells depend on an extrinsic
source of IL6 for their development and survival. High levels of
plasma IL6 have been associated with increased disease progres-
sion and decreased survival, thus providing the rationale for the
evaluation of combination therapies including drugs targeting IL6
for the treatment of this malignancy (102–104).
TARGETING INFLAMMATION AND TLRs IN CANCER
Constitutively, active NFκB signaling due to the aberrant activa-
tion of TLRs during chronic inflammation or by MYD88 mutation
determines the poor clinical outcome of many hematological
malignancies. Desirable outcomes in treating these diseases can
be achieved by using a combination of inhibition of signal trans-
ducers and transcription factors, sequestration of chemokines
and cytokines that sustain inflammatory cells, and the deple-
tion of immune or inflammatory cells that promote tumor
development.
Gain-of-function MYD88 mutations have emerged as a potent
driver of constitutively active NFκB signaling in many tumors.
Targeting this pathway is likely going to be useful as part of a
multi-component therapy for many hematological malignancies
that are addicted to NFκB activity for their survival. MYD88 sig-
naling is critically dependent on its homo-dimerization through
conserved residues within the BB-loop structure of the TIR
domain (29, 105). Interfering with this interaction by heptapep-
tides mimicking the BB-loop has achieved significant reduction in
NFκB activity (106). Another novel synthetic compound, ST2825,
developed by the same group of researchers is currently under
pre-clinical evaluation for the treatment of chronic inflamma-
tory diseases (107). Other peptide-based synthetic small mole-
cule inhibitors such as hydrocinnamoyl-l-valyl pyrrolidine (com-
pound 4a) and Pephinh-MYD88 have also been developed to tar-
get MYD88 dimerization in the treatment of lymphoma patients
with MYD88 mutations (108). However, these potential MYD88
specific therapeutic options are yet to be trialled in large clinical
cohorts.
Constitutive NFκB activity in certain lymphoid tumors sug-
gests that the activation of this pathway is crucial for their survival
and thus making them attractive drug targets for anti-cancer ther-
apy (62, 72, 109, 110). However in most cases, such therapy is
likely to be effective only in combination with more conven-
tional approaches. Furthermore, as genotoxic therapies often lead
to NFκB activation in remaining malignant cells, it makes sense
to combine genotoxic dugs with NFκB inhibitors to overcome
drug resistance. However, prolonged NFκB inhibition can result
in severe immune deficiency and may lead to neutrophilia and
greatly enhanced acute inflammation due to enhanced IL1β secre-
tion. Such complications as well as increase propensity for liver
damage have hindered the clinical development of NFκB and IKKβ
inhibitors (57, 111, 112). An attractive alternative target is the
STAT3 transcription factor and the signaling pathway that leads to
its activation (113, 114). Several STAT3 and JAK2 inhibitors have
been described and shown to inhibit the growth of various can-
cers that exhibit STAT3 activation (115, 116). So far, none of the
complications associated with NFκB inhibitor have been reported
for STAT3 or JAK2 inhibitors.
It is unlikely that inhibition of NFκB or STAT signaling alone
will be sufficient for tumor regression, yet the combination of
an NFκB inhibitor and an apoptosis inducing drug or cytokine
could be highly effective. Selective inhibition of NFκB in cancer
cells blocks the stimulatory effect of TNF and markedly increases
susceptibility to TRAIL-induced cell death, resulting in tumor
regression (117, 118). NFκB inhibition and anti-TNF therapy,
together with the administration of IFN or TRAIL might offer
an attractive combined strategy for immunomodulatory cancer
therapy. A recent study has found such synergy between lenalido-
mide and the BTK inhibitor Ibrutinib in killing ABC-DLBCL by
the induction of IRF7 and IFN-β production to cause cell cycle
arrest and apoptosis (119, 120). Combinatorial strategies provide
a distinct advantage where by certain IFN induced side-effects
might be diminished after NFκB inhibitor treatment, shifting the
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balance of cytokines in the tumor microenvironment to promote
tumor regression.
Although it is widely accepted that dampening inflammation
and diminishing TLR activity are beneficial for tumor regression,
several new lines of evidence have emerged to suggest that TLR
agonists could be used as potent anti-tumor agents. When treated
with a TLR9 agonist, type B CpG oligodeoxynucleotides (CpG-B
ODNs), and CLL B cells that selectively express high levels of TLR9
undergo profound apoptosis by the activation of STAT1, reduction
of Bcl-xl pro-survival protein, and elevation of Fas and Fas ligand
(121). TLR9 triggered apoptosis seems to be dependent on the
altered NFκB status of lymphoma cells compared to normal cells.
Moreover, the use of TLR agonists has been known to activate
the cognate immune system against cancer cells (122–124). TLRs
in lymphoid malignancies appear to be a “double-edged sword”
in actively driving disease progression in some but exhibit tumor
regressive roles in others. Activation of TLRs by MYD88 mutations
has often been associated with poor clinical outcome in lymphoma
patients. However, a recent study has reported improved patient
survival in a subset of young CLL patients with the identical muta-
tion (125). Interestingly, patients with MYD88 mutations were
much younger and had lower expression of CD38 and ZAP-70
than patients with unmutated MYD88. CD38 expression on CLL
cells is important for their proliferation and chemotaxis through a
signaling pathway involving ZAP-70 (90). Elevated CD38 expres-
sion often marks CLL patients with poor clinical outcome and
responsiveness to therapy (90). Complex interactions between
MYD88 mutation, IGHV mutation status, and CD38 and ZAP-
70 levels confound the explanation behind why patients with
MYD88 mutations had reduced CD38 expression and show better
survival (125).
CONCLUSION
Pattern recognition receptors protect us from danger and damage
associated signals, however, inappropriate activation of these path-
ways can cause cancer. TLRs can also use ubiquitously available
self-ligands such as our own DNA to drive aberrant cell growth
when the adaptor protein MYD88 is mutated. This recent finding
is one of the many pieces of supportive evidence for Virchow’s
hypothesis that chronic inflammation is linked with cancer devel-
opment. Studies into mutations in the TLR signaling pathways
have significantly advanced our understanding on the involve-
ment of TLRs in cancer. However, the potential for targeting TLRs
as anti-cancer therapy remains an area that is not yet fully under-
stood. Often TLRs act as a “double-edged sword” in cancer, over
active TLR signal provides a microenvironment that is necessary
for malignant cell proliferation; on the other hand, TLR agonists
can also be used to inhibit cancer cell growth. A better understand-
ing of the involvement of TLRs in cancer would help in tipping
the balance between tumor stimulatory and inhibitory effects and
the development of novel anti-cancer agents.
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